A novel, best-in-class small molecule program for the treatment of Tobacco Use Disorder. The limitations of current standards-of-care, such as varenicline (Chantix), are well-documented, including neuropsychiatric side effects and modest long-term efficacy, which stem from non-selective receptor activity. Our program represents a new generation of nicotine derivatives engineered for subtype selectivity. This approach aims to uncouple the therapeutic benefit from the negative side effect profile of existing treatments. The program is currently at the Nonclinical Phase 2 stage with a planned Phase IIa proof-of-concept study, which would provide a robust data package demonstrating clinical efficacy and a superior safety profile.